An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors ...

2, 4 Low-grade ICANS is treated with corticosteroids, with escalating doses for high-grade reactions. Other toxicities can coexist with CRS and ICANS Immune compromise, tumour flare, tumour lysis ...

The impact of pelvic radiotherapy on hematological outcomes in pediatric genitourinary rhabdomyosarcoma. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Pasithea's CEO, Dr. Tiago Reis Marques, expressed optimism about the safety profile of PAS-004, a macrocyclic MEK inhibitor with a half-life exceeding 60 hours. The company, whose stock is ...

Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on ...